| Name | 4-[(2S)-2-(4-cyanophenyl)-2-hydroxy-2-(3-methylimidazol-4-yl)ethoxy]-3-[4-(trifluoromethoxy)phenyl]benzonitrile |
|---|---|
| Synonyms |
ABT-100 (ABT100)
abt-100 [1,1'-Biphenyl]-3-carbonitrile, 6-[(2S)-2-(4-cyanophenyl)-2-hydroxy-2-(1-methyl-1H-imidazol-5-yl)ethoxy]-4'-(trifluoromethoxy) |
| Description | ABT-100 is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC50s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity[1]. |
|---|---|
| Related Catalog | |
| Target |
Farnesyltransferase[1] |
| In Vitro | ABT-100 (0.1-100 nM; 7 days; EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells) treatment shows dose-dependent growth inhibition of human cancer cell lines. Also inhibits colony formation at concentrations comparable with which ABT-100 inhibits anchorage-dependent growth[1]. Cell Proliferation Assay[1] Cell Line: EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells Concentration: 0.1-100 nM Incubation Time: 7 days Result: Demonstrated dose-dependent growth inhibition of human cancer cell lines. |
| In Vivo | ABT-100 (6.25-12.5 mg/kg/day; subcutaneous injection; daily; for 21 days; C.B-17 scid male mice) treatment regresses EJ-1 tumors in mice[1]. Animal Model: C.B-17 scid male mice with EJ-1 cells[1] Dosage: 6.25 mg/kg/day, 12.5 mg/kg/day Administration: Subcutaneous injection; daily; for 21 days Result: Regressed EJ-1 tumors in C.B-17 scid male mice. |
| References |
| Density | 1.29g/cm3 |
|---|---|
| Boiling Point | 722ºC at 760 mmHg |
| Molecular Formula | C27H19F3N4O3 |
| Molecular Weight | 504.46000 |
| Flash Point | 390.5ºC |
| Exact Mass | 504.14100 |
| PSA | 104.09000 |
| LogP | 5.04396 |
| Index of Refraction | 1.589 |
| Storage condition | -20°C |